Expertise in
4
conditions

Alasdair J. Coles

Cambridge, ENG, GB 
Expertise in
4
conditions
Cambridge, ENG, GB 
OverviewLocationsClinical Research

Overview

Alasdair Coles practices in Cambridge, United Kingdom. Mr. Coles is highly rated in 4 conditions, according to our data. His top areas of expertise are Multiple Sclerosis (MS), Relapsing Multiple Sclerosis (RMS), COVID-19, CACH Syndrome, and Bone Marrow Transplant.

His clinical research consists of co-authoring 129 peer reviewed articles and participating in 3 clinical trials. MediFind looks at clinical research from the past 15 years.

Gender
Male

Locations

Cambridge, ENG, United Kingdom
Other Locations
Sheffield, ENG, United Kingdom
London, ENG, United Kingdom

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

3 Clinical Trials

CCMR Two: A Phase IIa, Randomised, Double-blind, Placebo-controlled Trial of the Ability of the Combination of Metformin and Clemastine to Promote Remyelination in People With Relapsing-remitting Multiple Sclerosis Already on Disease-modifying Therapy
CCMR Two: A Phase IIa, Randomised, Double-blind, Placebo-controlled Trial of the Ability of the Combination of Metformin and Clemastine to Promote Remyelination in People With Relapsing-remitting Multiple Sclerosis Already on Disease-modifying Therapy
Enrollment Status: Active_not_recruiting
Publish Date: April 24, 2025
Intervention Type: Drug
Study Drug: Metformin+Clemastine
Study Phase: Phase 2
Determining the Effectiveness of earLy Intensive Versus Escalation Approaches for the Treatment of Relapsing-Remitting Multiple Sclerosis
Determining the Effectiveness of earLy Intensive Versus Escalation Approaches for the Treatment of Relapsing-Remitting Multiple Sclerosis
Enrollment Status: Active_not_recruiting
Publish Date: July 31, 2024
Intervention Type: Drug
Study Drugs: Early Highly Effective Therapies Group, Escalation Therapies Group
Study Phase: Phase 4
Keratinocyte Growth Factor - Promoting Thymic Reconstitution and Preventing Autoimmunity After Alemtuzumab (Campath-1H) Treatment of Multiple Sclerosis
Keratinocyte Growth Factor - Promoting Thymic Reconstitution and Preventing Autoimmunity After Alemtuzumab (Campath-1H) Treatment of Multiple Sclerosis
Enrollment Status: Terminated
Publish Date: April 30, 2019
Intervention Type: Drug
Study Phase: Phase 1/Phase 2
View 2 Less Clinical Trials

129 Total Publications

Approach to JCV testing with natalizumab biosimilar: a UK consensus statement.
Approach to JCV testing with natalizumab biosimilar: a UK consensus statement.
Journal: Multiple sclerosis and related disorders
Published: March 24, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Coles's expertise for a condition
ConditionClose
View All 22 Experienced Conditions
Want to save this expert for later?
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile